公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2011 | Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations | Wu J.-Y.; SHANG-GIN WU ; CHIH-HSIN YANG ; YIH-LEONG CHANG ; YEUN-CHUNG CHANG ; Hsu Y.-C.; JIN-YUAN SHIH ; PAN-CHYR YANG | Lung Cancer | 69 | 61 | |
2011 | Comparison of the quality of life between patients with non-small-cell lung cancer and healthy controls | Lee L.J.-H; Chung C.-W; Chang Y.-Y; Lee Y.-C; CHIH-HSIN YANG ; Liou S.-H; Liu P.-H; Wang J.-D. | Quality of Life Research | 32 | 28 | |
2007 | Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer | CHIA-CHI LIN ; CHIH-HUNG HSU ; CHIA-HSIEN CHENG ; HSIU-PO WANG ; JANG-MING LEE ; KUN-HUEI YEH ; CHIH-HSIN YANG ; Lin J.-T.; ANN-LII CHENG ; Lee Y.-C. | Annals of Oncology | 39 | 36 | |
2023 | Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies | Popat, Sanjay; Ahn, Myung-Ju; Ekman, Simon; Leighl, Natasha B; Ramalingam, Suresh S; Reungwetwattana, Thanyanan; Siva, Shankar; Tsuboi, Masahiro; Wu, Yi-Long; CHIH-HSIN YANG | Targeted oncology | 0 | 0 | |
2022 | Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations | Solomon, B J; Loong, H H; Summers, Y; Thomas, Z M; French, P; Lin, B K; Sashegyi, A; Wolf, J; CHIH-HSIN YANG ; Drilon, A | ESMO open | 7 | 6 | |
2010 | Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma | CHUN-TA HUANG ; RUOH-FANG YEN ; MEI-FANG CHENG ; Hsu Y.-C.; Wei P.-F.; Tsai Y.-J.; Tsai M.-F.; JIN-YUAN SHIH ; CHIH-HSIN YANG ; PAN-CHYR YANG | Medical Oncology | 61 | 54 | |
2022 | Cox Proportional Hazard Ratios Overestimate Survival Benefit of Immune Checkpoint Inhibitors: Cox-TEL Adjustment and Meta-Analyses of Programmed Death-Ligand 1 Expression and Immune Checkpoint Inhibitor Survival Benefit | Lin, Emily Pei-Ying; Hsu, Chih-Yuan; Chiou, Jeng-Fong; Berry, Lynne; Horn, Leora; Bunn, Paul; CHIH-HSIN YANG ; PAN-CHYR YANG ; Adjei, Alex A; Shyr, Yu | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 0 | 0 | |
2019 | Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors | JIH-HSIANG LEE ; Chen H.-Y.; Feng-Ming Hsu ; JIN-SHING CHEN ; WEI-YU LIAO ; JIN-YUAN SHIH ; CHONG-JEN YU ; KUAN-YU CHEN ; TZU-HSIU TSAI ; CHIH-HSIN YANG | Oncologist | 20 | 18 | |
1995 | Cross-Resistance to Camptothecin Analogues in a Mitoxantrone-resistant Human Breast Carcinoma Cell Line Is Not Due to DNA Topoisomerase I Alterations | CHIH-HSIN YANG ; Cowan K.H; Horton J.K; Schneider E. | Cancer Research | 100 | 96 | |
2018 | Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC | Gadgeel S; Shaw A.T; Barlesi F; Crinò L; CHIH-HSIN YANG ; Dingemans A.-M.C; Kim D.-W; De Marinis F; Schulz M; Liu S; Gupta R; Kotb A; Ou S.-H.I. | British Journal of Cancer | 21 | 21 | |
2008 | Current advanced statistical issues in clinical research---adaptive designs and translational medicine. | Hsiao C.F; Liu T.W; CHIH-HSIN YANG | Journal of the Formosan Medical Association = Taiwan yi zhi | 0 | 0 | |
2016 | Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in Taiwan: Daily Practice | YI-HSIN LIANG ; YU-YUN SHAO ; BIN-CHI LIAO ; Lee, Ho-Sheng; CHIH-HSIN YANG ; Chen, Ho-Min; CHUN-JU CHIANG ; ANN-LII CHENG ; Lai, Mei-Shu | Journal of Cancer | 8 | 7 | |
2014 | Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer | YEN-TING LIN ; YU-FEN WANG ; CHIH-HSIN YANG ; CHONG-JEN YU ; SHANG-GIN WU ; JIN-YUAN SHIH ; PAN-CHYR YANG | Journal of Thoracic Oncology | 50 | 38 | |
2013 | Diarrhea associated with afatinib: An oral ErbB family blocker | CHIH-HSIN YANG ; Reguart N; Barinoff J; Köhler J; Uttenreuther-Fischer M; Stammberger U; O'Brien D; Wolf J; Cohen E.E. | Expert Review of Anticancer Therapy | 91 | 86 | |
2004 | Differential effects of carboxyfullerene on MPP+/MPTP-induced neurotoxicity | Lin A.M.Y; CHIH-HSIN YANG ; Ueng Y.-F; Luh T.Y; Liu T.Y; Lay Y.P; Ho L.T. | Neurochemistry International | 28 | 27 | |
2005 | Docetaxel-induced recall dermatitis on previous laser treatment sites [2] | CHIA-YU CHU ; CHIH-HSIN YANG | British Journal of Dermatology | 6 | 5 | |
2018 | Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6) | Wu Y.-L; Hirsh V; Sequist L.V; Hu C.-P; Feng J; Lu S; Huang Y; Schuler M; Mok T; Yamamoto N; O’Byrne K; Geater S.L; Zhou C; Massey D; Märten A; Lungershausen J; CHIH-HSIN YANG | Patient | 20 | 17 | |
2018 | Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion | SHANG-GIN WU ; Liu Y.-N.; CHONG-JEN YU ; CHIH-HSIN YANG ; JIN-YUAN SHIH | Genes Chromosomes and Cancer | 11 | 10 | |
2018 | Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study | Garassino M.C; Cho B.-C; Kim J.-H; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray J.E; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo R.A; Huang Y; Wadsworth C; Dennis P.A; Rizvi N.A; Paz-Ares Rodriguez L; Novello S; Hiret S; Schmid P; Laack E; Califano R; Maemondo M; Kim S.-W; Chaft J; Vicente Baz D; Berghmans T; Kim D.-W; Surmont V; Reck M; Han J.-Y; Holgado Martin E; Belda Iniesta C; Oe Y; Chella A; Chopra A; Robinet G; Soto Parra H; Thomas M; Cheema P; Katakami N; Su W.-C; Kim Y.-C; Wolf J; Lee J.-S; Saka H; Milella M; Ramos Garcia I; Sibille A; Yokoi T; Kang E.J; Atagi S; Spaeth-Schwalbe E; Nishio M; Imamura F; Gabrail N; Veillon R; Derijcke S; Maeda T; Zylla D; Kubiak K; Santoro A; Uy M.N; Lucien Geater S; Italiano A; Kowalski D; Barlesi F; Chen Y.-M; Spigel D; Chewaskulyong B; Garcia Gomez R; Alvarez Alvarez R; CHIH-HSIN YANG ; Hsia T.-C; Denis F; Sakai H; Vincent M; Goto K; Bosch-Barrera J; Weiss G; Canon J.-L; Scholz C; Aglietta M; Kemmotsu H; Azuma K; Bradbury P; Feld R; Chachoua A; Jassem J; Juergens R; Palmero Sanchez R; Malcolm A; Vrindavanam N; Kubota K; Waller C; Waterhouse D; Coudert B; Mark Z; Satouchi M; Chang G.-C; Herzmann C; Chaudhry A; Giridharan S; Hesketh P; Ikeda N; Boccia R; Iannotti N; Haigentz M; Reynolds J; Querol J; Nakagawa K; Sugawara S; Tan E.H; Hirashima T; Gettinger S; Kato T; Takeda K; Juan Vidal O; Mohn-Staudner A; Panwalkar A; Daniel D; Kobayashi K; Ladrera G.E.I; Schulte C; Sebastian M; Cernovska M; Coupkova H; Havel L; Pauk N; Singh J; Murakami S; Csoszi T; Losonczy G; Price A; Anderson I; Iqbal M; Torri V; Juhasz E; Khanani S; Koubkova L; Levy B; Page R; Bocskei C; Crinò L; Einspahr D; Hagenstad C; Juat N; Overton L; Garrison M; Szalai Z; ATLANTIC Investigators | The Lancet Oncology | 468 | 397 | |
2012 | Dynamic contrast-enhanced MRI in advanced nonsmall-cell lung cancer patients treated with first-line bevacizumab, gemcitabine, and cisplatin | YEUN-CHUNG CHANG ; CHONG-JEN YU ; CHUNG-MING CHEN ; Hu F.-C.; Hsu H.-H.; WEN-YIH TSENG ; TIFFANY TING-FANG SHIH ; PAN-CHYR YANG ; Chih-Hsin CHIH-HSIN YANG | Journal of Magnetic Resonance Imaging | 52 | 43 | |